MX2021000280A - Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. - Google Patents
Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.Info
- Publication number
- MX2021000280A MX2021000280A MX2021000280A MX2021000280A MX2021000280A MX 2021000280 A MX2021000280 A MX 2021000280A MX 2021000280 A MX2021000280 A MX 2021000280A MX 2021000280 A MX2021000280 A MX 2021000280A MX 2021000280 A MX2021000280 A MX 2021000280A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- binding domain
- engineered
- compositions
- domain constructs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente descripción se refiere a composiciones y métodos de constructos de dominio de unión a antígeno-Fc modificados genéticamente, en donde los constructos de dominio de unión a antígeno- Fc incluyen al menos dos dominios Fc y al menos un dominio de unión a antígeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862696673P | 2018-07-11 | 2018-07-11 | |
PCT/US2019/041438 WO2020014505A2 (en) | 2018-07-11 | 2019-07-11 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000280A true MX2021000280A (es) | 2021-11-12 |
Family
ID=69141701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000280A MX2021000280A (es) | 2018-07-11 | 2019-07-11 | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210317227A1 (es) |
EP (1) | EP3820518A4 (es) |
JP (1) | JP2021530992A (es) |
KR (1) | KR20210043582A (es) |
CN (1) | CN113382749A (es) |
AU (1) | AU2019301684A1 (es) |
BR (1) | BR112021000415A2 (es) |
CA (1) | CA3106242A1 (es) |
IL (1) | IL280044A (es) |
MX (1) | MX2021000280A (es) |
WO (1) | WO2020014505A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230183353A1 (en) * | 2020-05-21 | 2023-06-15 | Zydus Lifesciences Limited | Fc variant and preparation thereof |
CN116888149A (zh) * | 2020-12-31 | 2023-10-13 | 信达生物制药(苏州)有限公司 | 含异二聚体抗体Fc的蛋白以及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2641913B1 (en) * | 2007-06-01 | 2018-04-18 | University of Maryland, Baltimore | Immunoglobulin constant region Fc receptor binding agents |
EP2409989A1 (en) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Method to improve glycosylation profile for antibody |
MX2014002289A (es) * | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
MX2015002269A (es) * | 2012-08-20 | 2015-07-06 | Gliknik Inc | Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente. |
EA201500741A1 (ru) * | 2013-01-10 | 2016-01-29 | Генмаб Б.В. | ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ |
UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
CA2941072A1 (en) * | 2014-05-02 | 2015-11-05 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
EP3347375B1 (en) * | 2015-09-10 | 2020-12-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-cd276 chimeric antigen receptors |
EP3423572B1 (en) * | 2016-03-02 | 2023-11-29 | Momenta Pharmaceuticals, Inc. | Methods related to engineered fc constructs |
IL263213B1 (en) * | 2016-05-23 | 2024-01-01 | Momenta Pharmaceuticals Inc | Compositions and methods relating to engineered FC constructs |
WO2018107082A1 (en) * | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
EP3565595A4 (en) * | 2017-01-06 | 2021-03-17 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS ASSOCIATED WITH DOMAIN CONSTRUCTIONS OF BINDING TO MANIPULATED FC ANTIGEN |
-
2019
- 2019-07-11 JP JP2021500881A patent/JP2021530992A/ja not_active Withdrawn
- 2019-07-11 AU AU2019301684A patent/AU2019301684A1/en not_active Abandoned
- 2019-07-11 KR KR1020217004250A patent/KR20210043582A/ko not_active Application Discontinuation
- 2019-07-11 WO PCT/US2019/041438 patent/WO2020014505A2/en unknown
- 2019-07-11 EP EP19833960.8A patent/EP3820518A4/en not_active Withdrawn
- 2019-07-11 BR BR112021000415-7A patent/BR112021000415A2/pt unknown
- 2019-07-11 CA CA3106242A patent/CA3106242A1/en active Pending
- 2019-07-11 CN CN201980059592.5A patent/CN113382749A/zh active Pending
- 2019-07-11 MX MX2021000280A patent/MX2021000280A/es unknown
- 2019-07-11 US US17/259,443 patent/US20210317227A1/en active Pending
-
2021
- 2021-01-10 IL IL280044A patent/IL280044A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL280044A (en) | 2021-03-01 |
WO2020014505A2 (en) | 2020-01-16 |
KR20210043582A (ko) | 2021-04-21 |
CN113382749A (zh) | 2021-09-10 |
AU2019301684A1 (en) | 2021-02-18 |
EP3820518A2 (en) | 2021-05-19 |
CA3106242A1 (en) | 2020-01-16 |
EP3820518A4 (en) | 2022-06-29 |
BR112021000415A2 (pt) | 2021-04-06 |
WO2020014505A3 (en) | 2020-02-20 |
JP2021530992A (ja) | 2021-11-18 |
US20210317227A1 (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4299595A3 (en) | Compositions and methods related to engineered fc constructs | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
PH12018502113A1 (en) | Chimeric receptors and methods of use thereof | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
PH12020551671A1 (en) | Chimeric receptors to dll3 and methods of use thereof | |
MX2019012953A (es) | Anticuerpo biespecifico contra ox40 y ctla-4. | |
MX2022012749A (es) | Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas. | |
MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
AU2016320748A8 (en) | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies | |
MX2021003555A (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g. | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
MX2020005662A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
CR20210091A (es) | Receptores químericos de steap1 y métodos de uso de los mismos antecedentes de la invención | |
MX2021000307A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. | |
MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000288A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000305A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000306A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4. | |
MX2021000281A (es) | Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1. | |
SA518391078B1 (ar) | (tslp) أجسام مضادة رابطة لليمفوبويتين السدوي الصعتري وطرق لاستخدام الأجسام المضادة |